Keywords
type 2 diabetes mellitus, ischemic heart disease, lipid metabolism, apolipoproteins.
How to Cite
Yefimov, A., & Sokolova, L. (2013). Dyslipoproteinemia and its role in development and progress of ischemic heart disease in patients with type 2 diabetes mellitus. Endokrynologia, 18(3), 28-33. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/373
Abstract
The results of the changes of lipid and lipoprotein metabolism in patients with type 2 diabetes types with different clinical course of CHD are presented. We found that in patients with type 2 diabetes, characterized by more severe coronary artery disease with prior history of acute cardiovascular events and cardiovascular deaths showed the most pronounced changes in atherogenic lipid and lipoprotein metabolism. The identified changes may be factors contributing to the progression of coronary artery disease in patients with DM type 2.
References
1. Roeters van Lennep J.E., Westerveld T., Roeters van Lennep W.O. et al. Apolipoprotein сoncentrations during treatment and recurrent coronary artery disease
events // Arteriosclerosis, Thrombosis, and Vascular Biology. 2000, 20, 2408-2413.
2. Братусь В.В., Лутай М.И., Талаева Т.В., Ломаковский А.Н. Актуальные аспекты патогенеза атеросклероза: холестерин, триглицериды, модифицированные липопротеины // Укр. кард. журнал. 2000, № 4, 5-13.
3. Братусь В.В., Талаева Т.В. Диабет и атерогенез. Роль диабетзависимых нарушений обмена липидов в ускоренном развитии атеросклероза // Укр. кардиол. журнал. 2001; 3: 84-89.
4. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice // Diabetologia. 2003, 46, 733-749.
5. Sniderman A.D., Scantlebury T., Cianflone К. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus // Ann Intern Med. 2001, 135, N 6, 447-459.
6. Koba S., Hirano T., Yoshino G. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes // Atherosclerosis. 2002, 160, 249-256.
7. Wаgner A.M., Pеrez A., Calvo F. et al. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2
diabetic patients // Diabetes Care. 1999, 22, 812-817.
8. Guerin M., Le Goff W., Lassel T.S. Proatherogenic role of elevated CE transfer from HDL to VLDL 1 and dense LDL in type 2 diabetes // Arterioscler Thromb Vasс
Biol. 2001, 21, 282-288.
9. Miremadi S., Sniderman A., Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders? //
Clinical Chemistry. 2002, 48, 484-488.
10. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipidlowering therapy // Circulation. 2002, 106, 2526-2529.
11. Jiang R., Schulze M.B., Li T. et al. Non-HDL Cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes // Diabetes Care. 2004, 27, 1991-1997.
12. Lamarche B., Despres J.P., Moorjani S. et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study) // Am. J. Cardiol. 1995, 75, 1189-1195.
13. Lopez-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy // J. Med. 2001, 32, 283-300.
14. Keech A., Colquhoun D., Best J. et al. LIPID study group secondary prevention of cardiovascular events with long-term Pravastatin in patients with diabetes or
impaired fasting glucose results from the LIPID trial // Diabetes Care. 2003, 26, 2713-2721.
15. Haas M.J., Horani M.H., Wong C.N.W., Mooradian A.D. Suppression of apolipoprotein A-I gene expression in HepG2 cells by TNFa and IL 1b // Biochim Biophys
Acta. 2003, 1623, 120-128.
events // Arteriosclerosis, Thrombosis, and Vascular Biology. 2000, 20, 2408-2413.
2. Братусь В.В., Лутай М.И., Талаева Т.В., Ломаковский А.Н. Актуальные аспекты патогенеза атеросклероза: холестерин, триглицериды, модифицированные липопротеины // Укр. кард. журнал. 2000, № 4, 5-13.
3. Братусь В.В., Талаева Т.В. Диабет и атерогенез. Роль диабетзависимых нарушений обмена липидов в ускоренном развитии атеросклероза // Укр. кардиол. журнал. 2001; 3: 84-89.
4. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice // Diabetologia. 2003, 46, 733-749.
5. Sniderman A.D., Scantlebury T., Cianflone К. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus // Ann Intern Med. 2001, 135, N 6, 447-459.
6. Koba S., Hirano T., Yoshino G. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes // Atherosclerosis. 2002, 160, 249-256.
7. Wаgner A.M., Pеrez A., Calvo F. et al. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2
diabetic patients // Diabetes Care. 1999, 22, 812-817.
8. Guerin M., Le Goff W., Lassel T.S. Proatherogenic role of elevated CE transfer from HDL to VLDL 1 and dense LDL in type 2 diabetes // Arterioscler Thromb Vasс
Biol. 2001, 21, 282-288.
9. Miremadi S., Sniderman A., Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders? //
Clinical Chemistry. 2002, 48, 484-488.
10. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipidlowering therapy // Circulation. 2002, 106, 2526-2529.
11. Jiang R., Schulze M.B., Li T. et al. Non-HDL Cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes // Diabetes Care. 2004, 27, 1991-1997.
12. Lamarche B., Despres J.P., Moorjani S. et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study) // Am. J. Cardiol. 1995, 75, 1189-1195.
13. Lopez-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy // J. Med. 2001, 32, 283-300.
14. Keech A., Colquhoun D., Best J. et al. LIPID study group secondary prevention of cardiovascular events with long-term Pravastatin in patients with diabetes or
impaired fasting glucose results from the LIPID trial // Diabetes Care. 2003, 26, 2713-2721.
15. Haas M.J., Horani M.H., Wong C.N.W., Mooradian A.D. Suppression of apolipoprotein A-I gene expression in HepG2 cells by TNFa and IL 1b // Biochim Biophys
Acta. 2003, 1623, 120-128.
Downloads
Download data is not yet available.